Overview

Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

Status:
Unknown status

Trial end date:
2020-05-01

Target enrollment:

Participant gender:

Summary

Patients enrolled into the study will be randomly allocated either to Empagliflozin group or control group. In the Empagliflozin group patients will be receiving standard care + Empagliflozin 10 mg o.d., in the control group patients will be receiving standard care without sodium glucose contransporter 2 (SGLT2) inhibitors.

Phase:

Phase 4

Details

Lead Sponsor:

Anton Borisov
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Collaborator:

Ministry of Health of the Russian Federation

Treatments:

Empagliflozin